P2Y12 Platelet Inhibitor [EPC] — Patent Landscape

Aggregated US Orange Book patent estate across every drug in the p2y12 platelet inhibitor [epc] class. 15 active patents protecting 2 drugs. First major cliff: 2029. Daily refresh.

2
Drugs in class
15
Active US patents
50/100
Avg vulnerability
$1.3B
Annual revenue covered

Originators

AstraZeneca 8 patents Chiesi 7 patents

Cliff calendar — next 15 years

1
29
5
30
1
33
4
35
4
36

Drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Brilinta
ticagrelor
 AstraZeneca 8 61 $1.1B 2030-04-17
Kengreal
CANGRELOR
 Chiesi 7 39 $200M 2029-05-13

Most attackable patents

Patent Drug Type Vuln Expiry
8425934 Brilinta other 68 2030-10-17
8425934 Brilinta other 68 2030-10-17
10300065 Brilinta method of use 62 2036-01-27
10300065 Brilinta method of use 62 2036-01-27
10300065 Brilinta other 62 2036-07-27
10300065 Brilinta other 62 2036-07-27
9925265 Kengreal method of use 58 2029-05-13
8425934 Brilinta formulation 53 2030-04-17
9427448 Kengreal method of use 51 2030-11-10
8425934 Brilinta formulation 48 2030-04-17

Strongest defences

Patent Drug Type Vuln Expiry
9439921 Kengreal formulation 25 2035-07-10
9295687 Kengreal formulation 25 2035-07-10
9700575 Kengreal formulation 25 2035-07-10
10039780 Kengreal method of use 45 2035-07-10
8680052 Kengreal method of use 45 2033-03-09
8425934 Brilinta formulation 48 2030-04-17
9427448 Kengreal method of use 51 2030-11-10
8425934 Brilinta formulation 53 2030-04-17
9925265 Kengreal method of use 58 2029-05-13
10300065 Brilinta other 62 2036-07-27

Related